2CUREX AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.439 SEK | +9.75% |
|
0.00% | -78.16% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.39M 679K | Sales 2022 | 3.37M 309K | Capitalization | 143M 13.18M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.65M | Net income 2022 | -29M -2.66M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.7M | Net cash position 2022 | 44.89M 4.12M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | +9.75% | ||
| Current month | +24.01% | ||
| 1 month | +4.52% | ||
| 3 months | -79.19% | ||
| 6 months | -84.65% | ||
| Current year | -78.16% |
1 week
0.36
0.44
1 month
0.300.58
Current year
0.292.79
1 year
0.297.50
3 years
0.2926.50
5 years
0.2931.50
10 years
0.2931.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.439 | +9.75% | 2 501 |
| 24-04-23 | 0.4 | +1.27% | 25,491 |
| 24-04-22 | 0.395 | -1.25% | 19,509 |
| 24-04-19 | 0.4 | -5.66% | 1,854 |
| 24-04-18 | 0.424 | -3.42% | 2,891 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 10:02 am EDT
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -78.16% | 650K | |
| -14.17% | 11.53B | |
| +46.13% | 3.31B | |
| -34.29% | 2.11B | |
| -18.60% | 2.05B | |
| -28.03% | 1.49B | |
| +18.02% | 1.02B | |
| -3.06% | 741M | |
| -32.92% | 426M | |
| -46.63% | 374M |
- Stock Market
- Equities
- 2CUREX Stock
